¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023³â ´ëÇÑÀ̽ÄÇÐȸ Á¦19Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-03-18

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023³â ´ëÇÑÀ̽ÄÇÐȸ Á¦19Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-03-18
±³À°ÀÏÀÚ : 2023-03-18
±³À°Àå¼Ò : ´ëÀüÄÁº¥¼Ç¼¾ÅÍ(DCC)

±³À°ÁÖÁ¦ : 2023³â ´ëÇÑÀ̽ÄÇÐȸ Á¦19Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑÀ̽ÄÇÐȸ
´ã´çÀÚ : ´ëÇÑÀ̽ÄÇÐȸ
¿¬¶ôó : 02-484-8052  

À̸ÞÀÏ : mykst@mykst.org

±³À°Á¾·ù : ³»°ú, ¿Ü°ú

Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ´ëÀü±¤¿ª½Ã
±³À°½Ã°£ : 19 ½Ã°£ 48ºÐ

¼¼ºÎ¼ö°­·á : 160,000¿ø  

ºñ°í »çÀüµî·Ï Á¤È¸¿ø: 10¸¸¿ø, ÁØȸ¿ø: 5¸¸¿ø, ºñȸ¿ø: 15¸¸¿ø ÇöÀåµî·Ï Á¤È¸¿ø: 12¸¸¿ø, ÁØȸ¿ø: 6¸¸¿ø, ºñȸ¿ø: 16¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 03-18 201È£ 08:00~08:30 Vitallink ÇöȲ º¸°í À̻■(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 08:30~09:00 KODA ÇöȲ º¸°í ¹®Àμº(KODA)

±³À°½Ã°£ 03-18 201È£ 09:00~09:30 KOTRY ÇöȲ º¸°í ±è¸í¼ö(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03-18 101/102È£ 08:00~08:20 ¼Ò¾Æ ³ú»ç±âÁõÀÚ ºÐ¼®°ú ¼öÇý °á°ú Æò°¡¿¡ ±âÃÊÇÑ Àå±â ºÐ¹è °³¼± ¹æ¾È ÃÖ¿µ·Ï(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 03-18 101/102È£ 08:20~08:40 °£¼¼Æ÷¾Ï ȯÀÚÀÇ »ýü °£ÀÌ½Ä ¼ö¼ú Àü°ú ÈÄÀÇ Ç÷û ³» ¿°Áõ¼º »çÀÌÅäÄ«ÀÎ ¹× ¹ÙÀÌ¿À¸¶Ä¿ ÃøÁ¤-ÇãÇ÷/Àç°ü·ù ¼Õ»ó ¹× °£¼¼Æ÷¾Ï Àç¹ß¿¡ ´ëÇÑ ¿¬°ü¼º ºÐ¼®À» À§ÇÑ ¼±Çà °úÁ¦ À¯Áø¼ö(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 03-18 101/102È£ 08:40~09:00 ½ÅÀåÀÌ½Ä ÈÄ ±â°è ÇнÀÀ» ÀÌ¿ëÇÑ À̽ĽŠ±â´É °¨¼Ò ¿¹Ãø ¸ðµ¨ ¹× À§Çè ÀÎÀÚ ¹ß±¼ ÀÌÀ¯È£(ºÐ´çÂ÷º´¿ø)

±³À°½Ã°£ 03-18 101/102È£ 09:00~09:20 ¿ì¸®³ª¶ó ¼Ò¾Æ °íÇüÀå±âÀÌ½Ä µî·Ï»ç¾÷ °­Èñ°æ(¼­¿ï´ëº´¿ø)

Åä·Ð 03-18 101/102È£ 09:20~09:30 Discussion ()

±³À°½Ã°£ 03-18 201È£ 09:30~09:45 Pretransplant workup & risk factor evaluation of alcohol relapse ¹ÚÁØ¿ë(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 09:45~10:00 Surgical outcones, living donor & allocation associated delemma ±èÈ¿½Å(Àü³²ÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 10:00~10:15 Ethical delemma cases ±èÇü¼÷(¼­¿ï¼º¸ðº´¿ø)

Åä·Ð 03-18 201È£ 10:15~10:30 Panel Discussion ¹ÚÁ¤ºÐ, ±èµ¿½Ä, ±Ç¿µ¶õ, ¹ÚÁØ¿ë, ±èÈ¿½Å, ±èÇü¼÷(KONOS, °í·ÁÀÇ´ë, Àü³²ÀÇ´ë, ¿¬¼¼ÀÇ´ë, Àü³²ÀÇ´ë, ¼­¿ï¼º¸ðº´¿ø)

ÈÞ½Ä 03-18 201È£, 101/102È£ 10:30~10:50 Coffee Break ()

±³À°½Ã°£ 03-18 201È£ 10:50~11:05 KT: Long-term outcome after kidney donation in Korea °­ÀºÁ¤(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 11:05~11:20 KT: Policy proposal to improve the outcome of kidney donor ÀåÇý·Ã(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 11:20~11:35 LT: Overview of long-term outcome of living liver donor ÇÑ´ëÈÆ(¼¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 03-18 201È£ 11:35~11:50 LT: Standard guideline for post-donation care in living liver donor ·ùÁ¦È£(ºÎ»êÀÇ´ë)

Åä·Ð 03-18 201È£ 11:50~12:20 Panel Discussion °­¸íÁø, Çã±ÔÇÏ, Á¶ÀåÈñ, Á¤µ¿È¯, ¹ÚÇýÀ±, ÃÖ±Ô¼º(º¸°Çº¹ÁöºÎ Ç÷¾×Àå±âÁ¤Ã¥°ú, ¿¬¼¼ÀÇ´ë, °æºÏÀÇ´ë, ¼­¿ï¾Æ»êº´¿ø, ¼­¿ï´ë, ¼º±Õ°üÀÇ´ë)

½Ä»ç 03-18 12:50~13:50 Luncheon Symposium ()

±³À°½Ã°£ 03-18 201È£ 13:50~14:00 ATG vs. basiliximab: Pro À̱³¿ø(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 14:00~14:10 ATG vs. basiliximab: Cons ±ÇÇö¿í(¿ï»êÀÇ´ë)

Åä·Ð 03-18 201È£ 14:10~14:20 Discussion ()

±³À°½Ã°£ 03-18 201È£ 14:20~14:30 Rituximab: necessity, dose, timing: Pro Á¤º´ÇÏ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 14:30~14:40 Rituximab: necessity, dose, timing: Cons ÀÌÁÖÇÑ(¿¬¼¼ÀÇ´ë)

Åä·Ð 03-18 201È£ 14:40~14:50 Discussion ()

±³À°½Ã°£ 03-18 201È£ 14:50~15:00 Early initiation of maintenance treatment: agent, dose, timing: Pro Á¤Ã¶¿õ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 15:00~15:10 Early initiation of maintenance treatment: agent, dose, timing: Cons ±è¿ëö(¼­¿ïÀÇ´ë)

Åä·Ð 03-18 201È£ 15:10~15:20 Discussion ()

±³À°½Ã°£ 03-18 101/102È£ 13:50~14:05 Down-staging for advanced HCC in LT - surgeon ¼Û±â¿ø(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03-18 101/102È£ 14:05~14:20 Down-staging for advanced HCC in LT - hepatologist À¯¼öÁ¾(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03-18 101/102È£ 14:20~14:35 Evolution in biomarkers to assess tumor biology ¹ÚÁØ¿ë(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03-18 101/102È£ 14:35~14:50 How to manage post-LT recurrence È«Á¤¿ë(¼º±Õ°üÀÇ´ë)

Åä·Ð 03-18 101/102È£ 14:50~15:20 Discussion ()

±³À°½Ã°£ 03-18 103/104È£ 13:50~14:08 Optimal Donor management protocol ÇöÁØÈ£(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03-18 103/104È£ 14:08~14:26 Organ preservation techniques for remote transplantation including preservation solutions ±èÁؼº(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03-18 103/104È£ 14:26~14:44 Marginal donor: expanding donor category ÁÖ¹ÎÈ£(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 03-18 103/104È£ 14:44~15:02 Heart transplantation after the circulatory death: what we need or how to prepare? ÀÌÇØ¿µ(¼­¿ïÀÇ´ë)

Åä·Ð 03-18 103/104È£ 14:02~15:20 Panel Discussion À̼±È­, Ȳȣ¿µ, Á¶¾çÇö, Á¤Àμ®, ÀÌÁÖÈñ(°è¸íÀÇ´ë, ¼­¿ïÀÇ´ë, ¼º±Õ°üÀÇ´ë, Àü³²ÀÇ´ë, ÃæºÏÀÇ´ë)

±³À°½Ã°£ 03-18 105È£ 13:50~13:58 Kidney allograft anti-GBM glomerulonephritis in a patient with Alport syndrome: Case presentation ¼ÛÁ¤ÀÎ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03-18 105È£ 13:58~14:06 Kidney allograft anti-GBM glomerulonephritis in a patient with Alport syndrome: Lab/Patho/Infection ¹®°æö(¼­¿ïÀÇ´ë)

Åä·Ð 03-18 105È£ 14:06~14:12 Discussion ()

±³À°½Ã°£ 03-18 105È£ 14:12~14:20 Uncovering atypical hemolytic uremic syndrome in a post-transplant end-stage kidney disease patient through CFH-22 deletion identification: Case presentation ÀÌÇÏÀº(¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 03-18 105È£ 14:20~14:28 Uncovering atypical hemolytic uremic syndrome in a post-transplant end-stage kidney disease patient through CFH-22 deletion identification: Lab/Patho/Infection ±èÈƼ®(¼­¿ï¼º¸ðº´¿ø)

Åä·Ð 03-18 105È£ 14:28~14:34 Discussion ()

±³À°½Ã°£ 03-18 105È£ 14:34~14:42 Malakoplakia after Kidney transplantation: Case presentation ÀÓ½ÂÇõ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03-18 105È£ 14:42~14:50 Malakoplakia after Kidney transplantation: Lab/Patho/Infection ÀÓ¹üÁø(¿¬¼¼ÀÇ´ë)

Åä·Ð 03-18 105È£ 14:50~14:56 Discussion ()

±³À°½Ã°£ 03-18 105È£ 14:56~15:04 pulmonary nocardiosis: Case presentation Çã°æ¹Î(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03-18 105È£ 15:04~15:12 pulmonary nocardiosis: Lab/Patho/Infection Çã°æ¹Î(¼º±Õ°üÀÇ´ë)

Åä·Ð 03-18 105È£ 15:12~15:18 Discussion ()

±³À°½Ã°£ 03-18 106È£ 13:50~14:20 Àå±âÀÌ½Ä À±¸®¿Í »ý¸í³ª´® ¼Õ¼±¿µ(¼¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 03-18 106È£ 14:20~14:50 Àå±âÀÌ½Ä ÇöÀåÀÇ À±¸®Àû À̽´¿Í ÇöȲ ±èÇü¼÷(¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 03-18 106È£ 14:50~15:20 Àå±âÀ̽ÄÄÚµð³×ÀÌÅÍÀÇ Àü¹®°¡·Î¼­ À±¸®Àû °¥µî ´ë¾È ¹× ±³À°ÀÇ Çʿ伺 À±Àº°æ(°æÈñ°£È£)

ÈÞ½Ä 03-18 201È£, 101~106È£ 15:20~15:40 Coffee Break ()

±³À°½Ã°£ 03-18 201È£ 15:40~16:10 Tolerization trials ½ÅÈ£½Ä(°í½ÅÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 16:10~16:40 Genomic study Á¤Á¾Ã¶(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03-18 201È£ 16:40~17:10 cfDNA, exosome ÀÌ»óÈ£(°æÈñÀÇ´ë)

±³À°½Ã°£ 03-18 101/102È£ 15:40~16:00 Basics in interpretation of LT pathology ±èÁöÈÆ(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 03-18 101/102È£ 16:00~16:20 ACR and CR in LT - pathopysiology and diagnosis Á¤Àº¼º(ÀºÆò¼º¸ð)

±³À°½Ã°£ 03-18 101/102È£ 16:20~16:40 Acute and chronic AMR in LT - pathopysiology and diagnosis ±èÇý·É(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03-18 101/102È£ 16:40~17:00 Liquid biopsy in LT pathology ¿ÀÀºÁö(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 03-18 103/104È£ 15:40~15:58 Recent changes in recipient registration and donor matching process ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø)

±³À°½Ã°£ 03-18 103/104È£ 15:58~16:16 Progression in pediatric heart transplantation ÀÌ»óÀ±(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03-18 103/104È£ 16:16~16:34 Challenges of heart transplantation: cardiac amyloidosis ±è´Ù·¡(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03-18 103/104È£ 16:34~16:52 Xenotransplantation À±Á¾Âù(°¡Å縯ÀÇ´ë)

Åä·Ð 03-18 103/104È£ 16:52~17:10 Panel Discussion °ûÀç°Ç, Á¶ÇöÀç, À̼ö¿ë, Àå¿ì¼º, ¿ÀÀç¿ø(¼­¿ïÀÇ´ë, ¼­¿ïÀÇ´ë, ºÎ»êÀÇ´ë, °è¸íÀÇ´ë, ¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03-18 105È£ 15:40~15:58 Induction protocol of Korean lung transplantation ¿©ÇýÁÖ(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 03-18 105È£ 15:58~16:16 Maintenance of immune medication ÀÓ¼ºÀ±(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03-18 105È£ 16:16~16:34 Prophylaxis of infection Àü°æ¸¸(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03-18 105È£ 16:34~16:52 PRA, cross matching and desensitization protocol ¿ì¾Æ¶ó(¿¬¼¼ÀÇ´ë)

Åä·Ð 03-18 105È£ 16:52~17:10 Panel Discussion ¹Ú¼ºÈÆ, ¹Ú»ùÀ̳ª, ÇÔ¼®Áø, ¹Ú¹«¼®(ÇѸ²ÀÇ´ë, ¼­¿ï´ë, ¾ÆÁÖÀÇ´ë, ¿¬¼¼ÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023³â ´ëÇÑÀ̽ÄÇÐȸ Á¦19Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-03-18""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â Á¦36Â÷ ´ëÇѳúÇ÷°ü¿Ü°úÇÐȸ Çмú´ëȸ ¹× ÃÑȸ (2ÀÏÂ÷) : 2023-03-18
´ÙÀ½±Û ´ëÇÑÃéÀå´ãµµÇÐȸ È£³²Áöȸ Á¦25ȸ Ãá°èÇмú´ëȸ : 2023-03-18
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 64 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 39 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 47 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 53 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 43 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 41 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 17 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 17 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 35 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 20 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 18 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 42 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 30 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 32 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 25 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷